Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | POLA1 | P09884 | 1/20 | 0.37 |
| ▸ | POLD1 | P28340 | 1/20 | 0.37 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.32 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.32 |
| ▸ | TK1 | P04183 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17066720 | 0.97 | POLB (0.37) | POLBPOLA1POLD1P2RY2P2RY6 | |
| SCHEMBL15799880 | 0.93 | POLB (0.38) | POLBPOLA1POLD1P2RY2P2RY6 | |
| SCHEMBL17636634 | 0.92 | POLB (0.37) | POLBPOLA1POLD1P2RY2P2RY6 | |
| SCHEMBL13891877 | 0.91 | POLB (0.35) | POLBPOLA1POLD1P2RY2P2RY6 | |
| SCHEMBL17227503 | 0.91 | POLB (0.35) | POLBPOLA1POLD1P2RY2P2RY6 | |
| SCHEMBL15799931 | 0.91 | POLB (0.39) | POLBPOLA1POLD1P2RY2P2RY6 | |
| SCHEMBL24548655 | 0.90 | GIGYF2 (0.38) | — | |
| SCHEMBL27102628 | 0.89 | POLB (0.39) | POLBPOLA1POLD1P2RY2P2RY6 | |
| SCHEMBL20821470 | 0.89 | POLB (0.34) | POLBPOLA1POLD1TK1 | |
| SCHEMBL19569904 | 0.89 | POLB (0.34) | POLBPOLA1POLD1TK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170002408-A1 | LABELLED NUCLEOTIDES | SOLEXA LIMITED (GB) | 2017-01-05 | — | — | US | disclosed |
| US-9410199-B2 | Labelled nucleotides | ILLUMINA CAMBRIDGE LIMITED (GB) | 2016-08-09 | — | — | US | disclosed |
| US-20150344516-A1 | LABELLED NUCLEOTIDES | SOLEXA LIMITED (GB) | 2015-12-03 | — | — | US | disclosed |
| US-20140141414-A1 | LABELLED NUCLEOTIDES | ILLUMINA CAMBRIDGE LIMITED (GB) | 2014-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170002408-A1 | LABELLED NUCLEOTIDES | NUDT1, DUT, NT5C2 | POLB 80/4885POLA1 126/4885POLD1 208/4885 |
| US-20150344516-A1 | LABELLED NUCLEOTIDES | NUDT1, DUT, NT5C2 | POLB 80/4885POLA1 126/4885POLD1 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.